Global DNA demethylation as an epigenetic marker of human brain metastases

Area of Science:

• Neuro-oncology
• Epigenetics
• Cancer Biology

Background:

• Brain metastases are the most common intracranial tumors in adults, often originating from lung, breast, renal, gastrointestinal cancers, or melanoma.
• Current treatments for brain metastases lack efficacy, highlighting the need for molecular approaches informed by genetic and epigenetic understanding.
• Epigenetic modifications, such as DNA methylation, are known to play a critical role in cancer development and progression.

Purpose of the Study:

• To investigate changes in 5-methylcytosine (m5C) levels in DNA from brain metastases and peripheral blood.
• To determine if DNA methylation patterns can serve as a diagnostic marker for brain metastases.
• To explore the correlation between m5C levels, tumor grade, and patient outcomes.

Main Methods:

• Global analysis of m5C content in DNA extracted from brain metastatic tumor tissue and matched peripheral blood samples.
• Utilized thin-layer chromatography separation of radioactively labeled nucleotides for m5C quantification.

Main Results:

• The level of m5C in DNA from brain metastases exhibited broad changes and overlapped with levels found in peripheral blood.
• A negative correlation was observed between m5C levels and increasing tumor grade.
• The concentration of m5C in tumor tissue and blood was found to be nearly identical.

Conclusions:

• Genomic DNA methylation, specifically m5C levels, shows potential as a non-invasive biomarker for the detection and differentiation of brain metastases.
• These findings open avenues for future research into epigenetic mechanisms in neuro-oncology.
• This research may contribute to the development of novel diagnostic methods for clinical application in brain tumor management.